Metabolic & Monogenic Diabetes Panel
Up to 5% of patients diagnosed with Type 2 diabetes actually have Monogenic Diabetes (MODY), an inherited single-gene disorder. Correct genetic classification can allow patients to transition from daily insulin injections to simple, well-tolerated oral sulfonylurea tablets, dramatically improving blood sugar control and quality of life.
Check If You Qualify
Takes under 2 minutes • 100% Covered under Medicare Part B
Who Should Consider This Screening?
Healthcare providers recommend this diagnostic panel for individuals with the following personal or family health indicators:
Biomarkers & Genes Evaluated in this Panel
Processed using high-complexity Next-Generation Sequencing (NGS) in CLIA-certified and CAP-accredited partner laboratories.
| Gene Symbol / Name | Clinical Significance | Actionable Impact |
|---|---|---|
| HNF1A & HNF4AHepatocyte Nuclear Factor 1 & 4 Alpha (MODY 3 & 1) | Regulates pancreatic beta-cell insulin secretion response to glucose. | Allows clinical transition from insulin to low-dose oral sulfonylureas with superior glycemic control. |
| GCKGlucokinase Pancreatic Glucose Sensor (MODY 2) | Controls the baseline fasting glucose threshold in liver and pancreas. | Confirms benign, stable mild hyperglycemia that typically requires zero medication, avoiding overtreatment. |
| PPARG & KCNJ11Insulin Sensitivity & Potassium Channel Subunits | Modulates peripheral insulin resistance and neonatal/atypical diabetes pathogenesis. | Directs personalized selection of GLP-1, SGLT-2, or oral hypoglycemic medication classes. |
Sample Report & Diagnostic Action Plan
Every patient receives an easy-to-understand diagnostic summary and a detailed clinical report tailored for their primary care doctor.
Heterozygous pathogenic mutation identified in HNF1A (c.872dupC, p.Pro291fs) confirming MODY 3.
Discuss with endocrinologist for potential transition from insulin therapy to oral low-dose glimepiride/gliclazide with continuous glucose monitoring.
Medicare Part B Coverage Guidelines
Understand how federal CMS medical necessity guidelines apply to this specific diagnostic screening:
Medicare Part B covers monogenic diabetes genetic testing when ordered by an attending physician to clarify diagnosis and tailor pharmacological management.
Ready to Check Your Eligibility for Metabolic & Monogenic Diabetes Panel?
Takes under 2 minutes • Painless at-home cheek swab • 100% Physician Reviewed